PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?

Cancers (Basel) · 2021 · PMC8464708 · PMID 34572747

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Another single-arm phase II study of rucaparib and temozolomide in advanced metastatic melanoma also showed improvement in progression-free survival but did not reach statistical significance [ 33 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.